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University of Bern, SwitzerlandBACKGROUND & AIMS: Cirrhosis and its clinical consequences
can be aggravated by bacterial infections, ultimately leading to
the development of acute on chronic liver failure (ACLF),
characterized by acute decompensation, organ failure, and high
mortality within 28 days. Little is known about cellular and
molecular mechanisms of ACLF in patients with cirrhosis, so no
therapeutic options are available. We developed a sepsis-
associated preclinical model of ACLF to facilitate studies of
pathogenesis and evaluate the protective effects of simvastatin.
METHODS: Male Wistar rats inhaled CCl4 until they developed
cirrhosis (at 10 weeks) or cirrhosis with ascites (at 15–16
weeks). Male Sprague-Dawley rats received bile-duct ligation
for 28 days or intraperitoneal thioacetamide for 10 weeks to
induce cirrhosis. After induction of cirrhosis, some rats received
a single injection of lipopolysaccharide (LPS) to induce ACLF;
some were given simvastatin or vehicle (control) 4 hours or 24
hours before induction of ACLF. We collected data on changes
in hepatic and systemic hemodynamics, hepatic microvascular
phenotype and function, and survival times. Liver tissues and
plasma were collected and analyzed by immunoblots, quanti-
tative polymerase chain reaction, immuno(ﬂuoro)histochemis-
try and immunoassays. RESULTS: Administration of LPS
aggravated portal hypertension in rats with cirrhosis byincreasing the severity of intrahepatic microvascular dysfunc-
tion, exacerbating hepatic inﬂammation, increasing oxidative
stress, and recruiting hepatic stellate cells and neutrophils. Rats
with cirrhosis given LPS had signiﬁcantly shorter survival times
than rats with cirrhosis given the control. Simvastatin pre-
vented most of ACLF-derived complications and increased
survival times. Simvastatin appeared to increase hepatic sinu-
soidal function and reduce portal hypertension and markers of
inﬂammation and oxidation. The drug signiﬁcantly reduced
levels of transaminases, total bilirubin, and ammonia, as well as
LPS-mediated activation of hepatic stellate cells in liver tissues
of rats with cirrhosis. CONCLUSIONS: In studies of rats with
cirrhosis, we found administration of LPS to promote devel-
opment of ACLF, aggravating the complications of chronic liver
disease and decreasing survival times. Simvastatin reduced
LPS-induced inﬂammation and liver damage in rats with ACLF,
supporting its use in treatment of patients with advanced
chronic liver disease.Keywords: ACLF; Animal Model; Cirrhosis; Decompensated;
E coli; Hepatic Microvascular Dysfunction; Hepatocytes;
Portal Hypertension.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Acute on chronic liver failure (ACLF) leads to acute
decompensation, organ failure and high mortality in
cirrhotic patients. However, its cellular and molecular
mechanism are unknown.
NEW FINDINGS
The authors developed and characterized a new pre-
clinical model of ACLF, evaluated the molecular and
cellular mechanisms involved, and tested simvastatin as
a potential therapeutic approach to treat ACLF.
LIMITATIONS
High mortality due to ACLF in decompensated cirrhotic
animals results in only a partial understanding of the
extrahepatic effects in this pre-clinical model.
IMPACT
The development of a new ACLF pre-clinical model
represents an important tool that may lead to a better
understanding of its pathophysiology and to generate
new therapeutics for patients suffering ACLF.
Simvastatin may be a novel and efﬁcient therapy in this
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Abbreviations used in this paper: ACLD, advanced chronic liver disease;
ACLF, acute-on-chronic liver failure; BDL, bile duct ligation; CCl4, carbon
tetrachloride; eNOS, endothelial nitric oxide synthase; HSC, hepatic stel-
late cells; HVR, hepatic vascular resistance; LPS, lipopolysaccharide; NET,
neutrophil extracellular trap; PBF, portal blood ﬂow; P-eNOS, phosphor-
ylated endothelial nitric oxide synthase; PP, portal pressure; PPVL, partial
portal vein ligation; TAA, thioacetamide.
Most current article
© 2018 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
0016-5085
https://doi.org/10.1053/j.gastro.2018.07.022
BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
LI
VE
RLized by extracellular matrix deposition leading to
ﬁbrous septa, formation of regenerative nodules, sinusoidal
microcirculatory dysfunction, and portal hypertension,
altogether ultimately leading to liver failure.1,2 Clinically,
cirrhosis progression follows 2 stages: a long compensated
one, usually asymptomatic and with good prognosis, fol-
lowed by a decompensated stage with poor prognosis,
heralded by the occurrence of complications such as ascites,
variceal bleeding, jaundice, and hepatic encephalopathy.3,4
At this stage, patients’ conditions can acutely deteriorate
as they rapidly develop hepatic encephalopathy, coagulop-
athy, acute kidney injury, and multiorgan failure, conﬁg-
uring the syndrome of acute on chronic liver failure
(ACLF).5,6 ACLF is deﬁned as an acute hepatic insult mani-
festing as jaundice and coagulopathy, complicated within 4
weeks by ascites and/or encephalopathy with high 28-day
mortality, and it is frequently precipitated by bacterial in-
fections and sepsis.5,7,8 To our knowledge, no experimental
model of ACLF has been developed and well characterized,
thus limiting the preclinical research in the ﬁeld.
Among the different therapeutic approaches proposed
for liver cirrhosis,9,10 recent studies have shown that statins
are among the most promising drugs for improving portal
hypertension and its complications.11,12 Statins are lipid-
lowering agents with immumodulatory, anti-inﬂammatory,
and vasoprotective effects.9 In particular, simvastatin is
able to improve the phenotype of sinusoidal cells, inhibiting
the activation and proliferation of hepatic stellate cells
(HSCs) and ensuing liver ﬁbrosis, ameliorating liver sinu-
soidal endothelial cells functionality, and reducing inﬂam-
mation and angiogenesis.13–16
Beneﬁcial effects of simvastatin have been recently
shown in double-blind randomized clinical trials to translateinto a decrease in portal pressure, improved quantitative
liver function test results, and increased survival in patients
with cirrhosis and portal hypertension.17,18 Moreover, sim-
vastatin has beneﬁcial effects on liver perfusion and
microvascular functionality in healthy rodents with bacte-
rial infection, suggesting a possible protective role during
endotoxemia,19 a concept that is further supported by
clinical observations of decreased prevalence of septic shock
and death in subjects receiving statins.20 Nevertheless, the
effect of simvastatin preventing ACLF syndrome in
compensated and decompensated cirrhotic rat models has
not been yet studied.
The current study aimed at developing a sepsis-related,
preclinical model of ACLF in rats with advanced chronic
liver disease (ACLD) and evaluating the possible protective
effects of acute simvastatin treatment on hepatic hemody-
namic, microvascular dysfunction, inﬂammation, and un-
derlying mechanisms involved.
Experimental Procedures
Animal Models and Treatments
Preclinical Rat Models of ACLD. Carbon Tetrachlo-
ride (CCl4) Inhalation. Male Wistar rats (50–75 g) underwent
CCl4 (Sigma-Aldrich, St. Louis, MO) inhalation 3 times a week
and received phenobarbital (0.3 g/L, Kern Pharma, Barcelona,
Spain) in the drinking water as previously described.13,21 A
high yield of micronodular cirrhosis with ascites was obtained
after 15 to 16 weeks. Administration of toxicants was stopped,
and treatments were started 1 week later.
A group of animals received CCl4 for only 10 weeks, and
animal treatments started 1 week later; this shorter CCl4
inhalation period caused cirrhosis but no animal developed
ascites.
Common Bile Duct Ligation (BDL). Secondary biliary
cirrhosis was induced in male Sprague-Dawley rats (200–225
g) by ligation of common bile duct for a period of 28 days.22
Treatments started on the 25th day when cirrhosis and asci-
tes had already developed.
Thioacetamide Administration (TAA). Male Sprague-
Dawley rats (150–200 g) received TAA (Sigma-Aldrich) dis-
solved in saline intraperitoneally at a dosage of 250 mg/kg
twice a week for 10 weeks without developing ascites.23
Treatments started 1 week later, after TAA administration
was stopped.
Preclinical Rat Model of Prehepatic Portal
Hypertension. Prehepatic portal hypertension was induced
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ligation (PPVL) as described.24 Brieﬂy, under isoﬂurane anes-
thesia, a calibrated constriction was performed using a single
ligature of 3-0 silk tied around the portal vein and a 19-gauge
blunt-tipped needle. The needle was then removed, leaving a
calibrated constriction of the portal vein.
Induction of Endotoxemia by Lipopolysaccharide
(LPS) Administration. Acute endotoxemia induced by
intraperitoneal or intravenous administration of LPS (from
Escherichia coli O111:B4, Sigma-Aldrich) was used to cause an
acute deterioration of cirrhosis, mimicking ACLF. This was done
at a dose of 1 mg/kg 4 hours before the hemodynamic study in
decompensated CCl4 and BDL animals, and compensated ani-
mals that received CCl4 or TAA for 10 weeks were treated with
LPS (1 mg/kg) 24 hours before the study. LPS doses and in-
cubation times were based on previous bibliography25,26 and
our own preliminary research.
Animals were caged in pairs on a 12:12-hour light-dark
cycle, in environmentally controlled animal facilities at the
Institut d’Investigacions Biomèdiques August Pi i Sunyer. All
experiments were approved by the Laboratory Animal Care and
Use Committee of the University of Barcelona and were con-
ducted in accordance with the European Community guidelines
for the protection of animals used for experimental and other
scientiﬁc purposes (EEC Directive 86/609).
Simvastatin Treatment. Rats were randomized to
receive simvastatin (Normon Laboratories, Madrid, Spain)
(25mg/kg/day in CCl4- and TAA-induced ACLD animals, 5 mg/
kg/day in BDL-induced animals) or water as vehicle compound,
administered orally by gavage once a day for 3 days, followed
by a fourth dose 30 minutes before the study. Nontoxic sim-
vastatin doses were based on previous studies and preliminary
data from our team27,28 and were prepared by a third person,
and experimental studies were realized blindly. Supplementary
Figure 1 summarizes the experimental groups included in the
study.
Hemodynamic Assessment and
Biochemical Analysis
Rats were anesthetized with ketamine hydrochloride (60
mg/kg; Merial Laboratories, Barcelona, Spain) plus midazolam
(3mg/kg; Laboratorios Reig Jofre, Barcelona, Spain) intraperito-
neally, fastened to a surgical board, and maintained a constant
temperature of 37C ± 0.5C. Tracheotomy and endotracheal
cannulation (PE-240 catheter; Portex, Minneapolis, MN) was
performed to maintain adequate respiration during anesthesia.
The femoral artery and the ileocolic vein were cannulated with
PE-50 catheters to measure mean arterial pressure (mm Hg) and
portal pressure (PP) (mm Hg), respectively. A nonconstrictive
perivascular ultrasonic transit time ﬂow probe (2PR, 2-mm
diameter; Transonic Systems Inc., Ithaca, NY) was placed
around the portal vein as close as possible to the liver to mea-
sure portal blood ﬂow (PBF) (mL/min).29 Hepatic vascular
resistance (HVR) (mm Hg$mL$min–1$g–1) was calculated as
PP/PBF. Blood pressures and ﬂows were registered on a
multichannel, computer-based recorder using Chart, version
5.0.1, for Windows software (PowerLab; AD Instruments, Colo-
rado Springs, CO). Hemodynamic data were collected after a
20-minute stabilization period. At the end of the hemodynamic
study, serum samples were collected to evaluate alanine
aminotransferase, aspartate aminotransferase, total bilirubin,albumin, creatinine, sodium, and ammonia levels, all by standard
protocols.
Hepatic Vascular Functionality Analysis
After in vivo hemodynamic assessment, livers were isolated
and perfused by a ﬂow-controlled perfusion system as previ-
ously described.30,31 The perfused rat liver preparation was
allowed to stabilize for 20 minutes, and portal perfusion
pressure was analyzed before vasoactive substances were
added. Precontraction was performed with the a-adrenergic
agonist methoxamine (104 mol/L, Sigma-Aldrich). After 5
minutes, increasing concentrations of acetylcholine (107, 106
and 105 mol/L; Sigma-Aldrich) were added to the system to
test the vasodilatory capacity of the liver circulation to ascer-
tain the sinusoidal microcirculatory function.14 Gross appear-
ance of the liver, stable perfusion pressure, bile production
over 0.4 mL/min/g of liver, and stable buffer pH (7.4 ± 0.1)
were monitored during the entire study.
Endotoxemia Quantiﬁcation
Endotoxemia was quantiﬁed using LAL Chromogenic
Endotoxin Quantitation Kit (Thermo Fisher Scientiﬁc, Waltham,
MA), following manufacturer’s instructions.
Protein Expression Analysis
Protein expression was determined by Western blot in all
hepatic and cell samples as previously described13 using anti-
bodies shown in Supplementary Table 1. Blots were visualized
by chemiluminescence, and digital images were taken using a
luminescent image analyzer LAS-4000 (General Electric, Little
Chalfont, Buckinghamshire, UK). Protein expression was
determined by densitometric analysis using the Science Lab
2001, Multi Gauge V2.1 (Fuji Photo Film, Düsseldorf, Germany).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used for the normalization of quantitative densitometry values.
The ratio between the densitometry readings of phosphory-
lated endothelial nitric oxide synthase (P-eNOS) and endothe-
lial nitric oxide synthase (eNOS) blots was calculated to
evaluate the degree of eNOS phosphorylation at Ser1176.
Circulating cytokines were determined in plasma samples
using a cytokine array (R&D Systems, Minneapolis, MN),
following the manufacturer’s instructions.
Neutrophil gelatinase–associated lipocalin was quantiﬁed in
serum samples using a rat neutrophil gelatinase–associated
lipocalin ELISA kit (Cusabio Technology, Houston, TX),
following the manufacturer’s instructions.
Messenger RNA Expression Analysis
Gene expression was analyzed in total RNA from all hepatic
and cell samples according to the manufacturer’s protocol using
primers described in Supplementary Table 2. Values were re-
ported relative to the endogenous control glyceraldehyde-3-
phosphate dehydrogenase. All ampliﬁcation reactions were
performed in duplicate, and nuclease-free water was used as
no-template control in the reaction sets.
Immunostaining and Microscopy
Immunostaining of parafﬁn-embedded liver sections was
performed with antibodies shown in Supplementary Table 1
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ﬁelds from each slide at 400 magniﬁcation were randomly
selected, and photographs were taken using a ﬂuorescent
microscope (Olympus, Tokyo, Japan) and quantiﬁed with
Image J 1.33u software (National Institutes of Health,
Bethesda, MD). Inﬁltrated neutrophils were characterized as
myeloperoxidase-positive cells, and their activity was char-
acterized as presence of neutrophil extracellular traps (NETs)
(structures double-positive for myeloperoxidase and histone
2B).32 Two independent researchers performed immuno-
staining quantiﬁcations blindly.Measurement of Superoxide (O2
–) Levels
in Liver Tissue
Oxidative stress in liver tissue was evaluated with the
ﬂuorescent dye dihydroethidium (Molecular Probes, Eugene,
OR).33 Six ﬁelds from each slide at 200 magniﬁcation were
randomly selected. Fluorescent images were obtained with a
ﬂuorescent microscope, and quantitative analysis was per-
formed with Image J 1.33u software.34Quantiﬁcation of Hepatic Fibrosis
Fixed livers were stained with 0.1% Sirius Red (Sigma-
Aldrich). Slices were photographed at 50 magniﬁcation using
a microscope equipped with a digital camera. Red-stained area
was measured using AxioVision software35 and divided by total
photographed area. Values were expressed as the mean per-
centage of 8 ﬁelds per sample.BA
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Immortalized HSCs (LX2 cells, kindly provided by Dr
Bataller) were maintained at 37C under an atmosphere of 5%
CO2 in complete Dulbecco’s modiﬁed Eagle medium (Gibco,
Thermo Fisher Scientiﬁc) containing 10% fetal bovine serum
(Biological industries, Cromwell, CT) and 1% penicillin/strep-
tomycin (Biological Industries).15
Neutrophils were isolated from human healthy volun-
teers’ peripheral blood by density centrifugation using a
Histopaque-1077 (Sigma-Aldrich) gradient.36 Brieﬂy, blood
samples were collected in tubes containing heparin (Labo-
ratorios Rovi, Barcelona, Spain). Plasma was discarded, and
blood was diluted in saline solution. Histopaque-1077 was
added and centrifuged at 700g at room temperature for 20
minutes. After centrifugation, the supernatant was removed,
and the residual erythrocytes were eliminated by hypotonic
lysis buffer, containing 0.83% NH4Cl (Sigma-Aldrich) and
washed in phosphate-buffered saline. Neutrophils were
maintained in RPMI 1640 medium (Biological Industries)
supplemented with 10% fetal bovine serum and 1% peni-
cillin/streptomycin at 37C in a humidiﬁed atmosphere con-
taining 5% CO2.
36,37
Neutrophils were pretreated with vehicle (0.001% dimethyl
sulfoxide, Sigma-Aldrich) or simvastatin (1–5 mmol/L) for 1
hour, treated with LPS (100 ng/mL) or vehicle for 4 hours, and
afterwards co-cultured with HSC for 16 hours. Direct co-culture
assays were performed by adding 2  104 neutrophils to 6 
104 LX2 cells. In indirect co-culture experiments, LX2 cells were
co-cultured with neutrophils in 12-well Transwell plates (0.4
mm/pore; Corning Inc, Corning, NY).38Statistical Analysis
Statistical analysis was performed using the SPSS 19.0
statistical package (IBM, Armonk, NY). Data are reported as
mean ± standard error of the mean. Survival analyses were
done using the log-rank (Mantel-Cox) test comparing groups.
Analysis of variance test and Tukey post hoc test were used for
analyzing differences between groups. Differences were
considered signiﬁcant at P < .05.
Results
Systemic Effects of LPS Administration in
Cirrhotic Rats
Exogenous administration of LPS to cirrhotic animals
markedly elevated endotoxemia, which correlated with se-
vere detrimental effects on systemic hemodynamic and
renal function (Supplementary Figure 2). Effects of LPS on
hepatic hemodynamic and function are described in the next
section.
LPS Administration Aggravates Portal
Hypertension and Liver Microcirculatory
Dysfunction in Rats With Cirrhosis; Simvastatin
Treatment Prevents ACLF Deleterious Effects
Intraperitoneal LPS administration markedly increased
PP in decompensated and compensated CCl4 cirrhotic rats
(þ11% and þ28%, respectively), with the same trend in
compensated TAA cirrhotic animals (þ20%) (P ¼ .06)
(Table 1). No changes in PBF were observed, thus suggest-
ing that portal hypertension aggravation in ACLF was
derived from an increment in the HVR (decompensated
cirrhotic rats: þ94% in CCl4, compensated: þ57% in CCl4
and þ130% in TAA). Intravenous administration of LPS led
to similar deleterious effects (þ57% in PP and þ64% in
HVR) (Supplementary Table 3). No signiﬁcant hemodynamic
changes were observed in decompensated BDL rats. In
addition, no aggravation in portal pressure was observed in
a group of animals with prehepatic portal hypertension due
to PPVL (14.6 ± 2.5 mmHg in PPVL þ vehicle vs 15.1 ± 1.2
mm Hg in PPVL þ LPS).
Analysis of hepatic microcirculation ex vivo further
conﬁrmed the aggravation in liver microvascular dysfunc-
tion during ACLF, as shown by marked increments in portal
perfusion pressure (Figure 1, top) and the attenuation of the
hepatic vasodilatory response to acetylcholine (Figure 1,
bottom).
Scrutiny of a possible therapeutic intervention for ACLF
showed that simvastatin prevented the LPS-induced aggra-
vation in portal hypertension. Indeed, animals treated with
simvastatin showed signiﬁcantly lower PP after ACLF chal-
lenge than those receiving vehicle þ LPS (decompensated
cirrhotic rats: –21% in CCl4 and –22% in BDL, compensated:
–20% in TAA). No changes in PBF were observed, further
suggesting a reduction in HVR as the cause for the
improvement in PP. Indeed, HVR was reduced in response
to simvastatin in decompensated CCl4 rats (–35%), although
this was not observed in BDL animals. Simvastatin treat-
ment resulted in no signiﬁcant changes in PBF or HVR in
Table 1.Effects of LPS and Simvastatin on Hepatic and Systemic Hemodynamic in Rats With Decompensated and
Compensated ACLD
Parameters
Decompensated ACLD
CCl4 BDL
Vehicle Vehicle þ LPS Simvastatin þ LPS Vehicle Vehicle þ LPS Simvastatin þ LPS
Number of animals 9 12 9 8 7 8
MAP (mm Hg) 79 ± 16 100 ± 15a 112 ± 25a 74 ± 9 60 ± 10 71 ± 28
PP (mm Hg) 12.2 ± 1.9 13.5 ± 2.7a 10.7 ± 1.9b 15.2 ± 2.0 13.9 ± 2.2 10.8 ± 2.1a,b
PBF (mL/min) 18.5 ± 7.6 15.9 ± 8.7 16.2 ± 6.1 18.9 ± 8.6 20.6 ± 4.8 17.1 ± 7.2
HVR (mm Hg/mL$min–1$g–1) 6.8 ± 3.2 13.2 ± 6.8a 8.6 ± 2.6b 21.4 ± 10.4 20.2 ± 7.3 22.6 ± 13.0
HR (beats/min) 298 ± 51 368 ± 29a 382 ± 62a 345 ± 33 388 ± 46 426 ± 37b
Liver weight (g) 11.7 ± 1.8 11.8 ± 2.1 13.0 ± 2.5 25.0 ± 6.6 27.7 ± 8.4 27.4 ± 4.9
Body weight (g) 369 ± 49 367 ± 52 404 ± 70 413 ± 95 378 ± 134 394 ± 75
Compensated ACLD
CCl4 TAA
Vehicle Vehicle þ LPS Simvastatin þ LPS Vehicle Vehicle þ LPS Simvastatin þ LPS
Number of animals 5 6 6 4 3 5
MAP (mm Hg) 97 ± 16 88 ± 21 116 ± 23b 89 ± 20 108 ± 27 110 ± 15
PP (mm Hg) 8.6 ± 1.5 11.0 ± 1.5a 10.4 ± 0.9a 10.2 ± 0.5 12.3 ± 1.3 9.8 ± 1.5b
PBF (mL/min) 13.4 ± 4.1 15.2 ± 4.7 10.9 ± 2.9 18.9 ± 1.9 13.9 ± 11.0 17.3 ± 4.0
HVR (mm Hg/mL$min–1$g–1) 6.3 ± 1.6 9.9 ± 4.8 11.2 ± 4.6 7.3 ± 0.6 16.8 ± 10.6 9.0 ± 2.7
HR (beats/min) 369 ± 24 384 ± 90 423 ± 50 352 ± 61 366 ± 24 354 ± 35
Liver weight (g) 9.4 ± 1.9 12.3 ± 2.1a 10.7 ± 2.2 13.9 ± 1.2 14.0 ± 1.8 14.9 ± 0.9
Body weight (g) 333 ± 27 382 ± 39a 365 ± 21 358 ± 32 332 ± 35 393 ± 31b
NOTE. Values represent mean ± standard deviation.
HVR, hepatic vascular resistance; MAP, mean arterial pressure; PBF, portal blood ﬂow; PP, portal pressure; TAA,
thioacetamide.
aP < .05 vs vehicle.
bP < .05 vs vehicle þ LPS.
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was slightly ameliorated in rats treated with simvastatin
(Table 1).
In agreement with the improvement observed in vivo,
simvastatin also prevented the hemodynamic deterioration
from LPS-induced ACLF in ex vivo portal perfusion pressure
(Figure 1, top) and in the hepatic vasodilatory response to
acetylcholine (Figure 1, bottom).ACLF Exacerbates Inﬂammation and Oxidative
Stress, Effects of Statins
LPS promoted a marked aggravation in systemic and
hepatic inﬂammation in cirrhotic rats, as shown by signiﬁ-
cant changes in pro- and anti-inﬂammatory mediators
(Figure 2 and Supplementary Figures 3 and 4). This in-
ﬂammatory burst was associated with signiﬁcant in-
crements in hepatic neutrophil inﬁltration and neutrophil
activity measured as formation of NETs (Figure 3 and
Supplementary Figure 5). Simvastatin treatment prevented
the inﬂammatory burst due to endotoxemia in decom-
pensated cirrhotic rats, although its anti-inﬂammatory ef-
fects were less evident in the BDL preclinical model
(Figures 2 and 3 and Supplementary Figures 3 and 4).A similar trend was observed in compensated CCl4 rats
(Supplementary Figure 5).
LPS exacerbated hepatic oxidative stress in decom-
pensated cirrhotic rats, as shown by signiﬁcantly elevated
levels of superoxide and nonsigniﬁcant increment in per-
oxynitrite (Figure 4A and B). Oxidant deregulations
were associated with a marked decrease in hepatic eNOS
activation (Figure 4C and D). Simvastatin prevented the
ACLF-derived increase in oxidative stress in both decom-
pensated cirrhotic models (Figure 4A and B) and improved
the P-eNOS/eNOS ratio in the CCl4 model (Figure 4C) but
not in the BDL model (Figure 4D).
Inﬂammatory and oxidative markers in livers from
compensated cirrhotic rats receiving LPS exhibited the same
trend observed in decompensated cirrhotic animals,
although it did not reach statistical signiﬁcance (data not
shown).LPS Administration Worsens the Phenotype
of Hepatic Stellate Cells, Which Is Prevented
by Simvastatin
Further analysis of the molecular and cellular mecha-
nisms underlying the liver microcirculatory aggravation
Figure 1. Effects of ACLF on hepatic microvascular function in rats with ACLD treated with simvastatin or vehicle. Top, portal
perfusion pressure (PPP) was evaluated in rats with decompensated ACLD (dACLD) or compensated ACLD (cACLD) treated
with vehicle (Veh), vehicle þ LPS (Veh þ LPS), or simvastatin þ LPS (Simva þ LPS). Bottom, liver vasodilatory response to
incremental doses of acetylcholine was evaluated in animals described above. Values represent mean ± standard error of the
mean. *P < .05. Number of animals included in each experimental group is deﬁned in Table 1.
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activation in decompensated cirrhotic animals, shown by
increased hepatic a-smooth muscle actin expression both at
messenger RNA and protein levels (Figure 5), with no
changes in liver ﬁbrosis (data not shown). Simvastatin did
not modify liver ﬁbrosis but prevented the LPS-mediated
HSC activation in both decompensated cirrhotic rat models
(Figure 5).
In addition, and considering the increment in neutrophil
inﬁltration during ACLF, we ascertained whether LPS-
activated neutrophils might inﬂuence HSC phenotype. As
shown in Supplementary Figure 6, direct co-culture of
activated neutrophils with LX2 cells caused HSC over-
activation, which was not observed when indirect co-culture
(Transwell) was performed (data not shown). The detri-
mental effects of LPS-stimulated neutrophils on the LX2
phenotype were partly abrogated by simvastatin
(Supplementary Figure 6), altogether suggesting a possible
role of neutrophils partly mediating HSC activation during
LPS-induced ACLF.ACLF Negatively Affects Cirrhotic Animals’
Survival and Is Prevented by Simvastatin
Rat survival was monitored during 4 or 24 hours (in
decompensated or compensated cirrhotic animals, respec-
tively) after LPS administration. No mortality was observed
in decompensated and compensated cirrhotic animals
without ACLF. On the contrary, signiﬁcant mortality was
observed in LPS-treated groups, especially in the decom-
pensated cirrhotic models (66.6% survival in CCl4, P ¼ .05;
58.3% survival in BDL, P < .05) (Table 2). Corresponding
data in compensated cirrhotic models were as follows: CCl4:
75% survival after intraperitoneal LPS, P ¼ .48; 66.7%
survival after intravenous LPS, P ¼ .08; TAA: 50% survival,
P ¼ .13) (Table 2 and Supplementary Table 3). Detrimental
effects of LPS-induced ACLF were further conﬁrmed by
marked worsening of biochemical tests in surviving rats
(Table 3).
Simvastatin pretreatment improved survival of LPS-
induced ACLF in decompensated cirrhotic models (CCl4:
100% survival, P < .05; BDL: 89% survival, P ¼ .07)
Figure 2. Hepatic inﬂammation in rats with decompensated ACLD suffering ACLF. Inﬂammatory markers were evaluated in
rats treated with vehicle (Veh, n ¼ 9), vehicle þ LPS (Veh þ LPS, n ¼ 12), or simvastatin þ LPS (Simva þ LPS, n ¼ 9) in a CCl4
decompensated ACLD model at the (A) messenger RNA (mRNA) and (B) protein levels. Values represent mean ± standard
error of the mean. *P < .05.
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bilirubin, and ammonia levels (Table 2). A similar trend was
observed in compensated cirrhotic rats (CCl4: 86% survival,
P ¼ .43; TAA: 83% survival, P ¼ .18) (Tables 2 and 3).Discussion
ACLD is classiﬁed in compensated and decompensated
stages, with the presence of ascites, variceal hemorrhage,
jaundice, and/or hepatic encephalopathy being the most
common hallmarks of decompensation.39,40 Approximately
24%–40% of patients with ACLD will eventually develop
ACLF, which leads to a markedly decreased life expectancy.
ACLF denotes an acute deterioration of liver failure leading
to multiorgan failure, and it is thought to be due to
increased systemic inﬂammation.41 However, there is no
speciﬁc treatment available for correcting or preventing
ACLF.
The present study aimed at evaluating the possible ef-
ﬁcacy of simvastatin, a compound with vasoprotective and
anti-inﬂammatory activity, in preventing ACLF in experi-
mental models of ACLD. Before that, and considering that toour knowledge no validated model of ACLF has been re-
ported, we characterized the effects of ACLF on hepatic
hemodynamic microcirculatory function and survival in
validated models of compensated and decompensated
chronic liver disease. To this end, we used LPS adminis-
tration to precipitate ACLF in these experimental models,
because sepsis/bacterial infections are clinically the most
common precipitant of ACLF in human cirrhosis.
At the hemodynamic level, we observed that LPS
administration signiﬁcantly affected the intrahepatic sinu-
soidal function, leading to increased intrahepatic vascular
resistance and consequently aggravated portal hyperten-
sion. This relevant effect of ACLF, which agrees with clinical
observations,42 was not seen in the BDL model, probably
because this is a much more aggressive model of cirrhosis
with endogenous altered gut permeability, and therefore
LPS did not further aggravate portal hypertension due to
preexisting endotoxemia. Indeed, in compensated cirrhotic
models, with lower spontaneous bacterial translocation, LPS
increased portal pressure, further suggesting a greater
impact of endotoxemia when there is no previous bacterial
translocation. LPS administration did not modify portal
Figure 3. Detection of neutrophils and NETs in rats with decompensated ACLD suffering ACLF. Neutrophils (MPO-positive
cells) and NETs (structures double-positive for MPO and histone 2B, arrows) were evaluated in liver tissue from CCl4
decompensated ACLD rats treated with vehicle (Veh, n ¼ 9), vehicle þ LPS (Veh þ LPS, n ¼ 12) or simvastatin þ LPS (Simva þ
LPS, n ¼ 9). Representative image original magniﬁcation, 400; (A) and (B) quantiﬁcations. Values represent mean ± standard
error of the mean. *P < .05. H2B, histone-2B; MPO, myeloperoxidase.
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suggesting that endotoxemia per se does not inﬂuence
portal pressure in the absence of liver injury.
In fact, we observed a global aggravation of hepatic
microvascular function during the development of ACLF,
with increased resistance and impaired endothelial-
dependent vasodilatation, which is in keeping with previ-
ous studies reporting systemic hyporesponsiveness to
vasoconstrictors and vascular damage during sepsis.25,43
The aggravation of liver microvascular function triggered
by LPS might partially be due to a combination of decreased
production of the vasodilator nitric oxide, as shown by
decreased P-eNOS/eNOS ratio, and increased oxidative
stress, which profoundly affects the hepatic vascular resis-
tance in cirrhotic livers.9 Contrarily, we did not observe
modulation of mesenteric vascular tone in response to LPS.
This paradoxical effect may be due to the preexistingendogenous endotoxemia that would activate per se
splanchnic vasodilatory pathways, including the nitric oxide
machinery44 and would not further respond to exogenous
LPS challenge.
Additionally, it is well known that oxidative stress is also
involved in HSC activation,45 and therefore it may not only
contribute to liver microvascular dysfunction but also
enhance ﬁbrosis. Indeed, we observed activation of HSC in
LPS-treated rats, although no signiﬁcant changes in liver
ﬁbrosis were seen, probably because of the short post-LPS
observation period.
As hypothesized, we observed a marked increase in
systemic and hepatic inﬂammation markers in this ACLF
model, observations in agreement with previous studies
showing systemic inﬂammation in ACLF patients.6,46 In
addition, increased hepatic neutrophil inﬁltration and NETs
were found, which agrees with clinical observations
Figure 4. Analysis of oxidative stress and nitric oxide pathways in rats with decompensated cirrhosis suffering ACLF pre-
treated with simvastatin or vehicle. Hepatic oxidative stress was evaluated by DHE staining and nitrotyrosine protein
expression in rats treated with vehicle (Veh, n ¼ 9), vehicle þ LPS (Veh þ LPS, n ¼ 12) or simvastatin þ LPS (Simva þ LPS, n ¼
9) in (A) CCl4 and (B) BDL (Veh, n ¼ 8; Veh þ LPS, n ¼ 7; Simva þ LPS, n ¼ 8) dACLD. P-eNOS/eNOS ratio was analyzed in the
same groups described in (C) CCl4 and (D) BDL dACLD. Values represent mean ± standard error of the mean. *P < .05. DHE,
dihydroethidium.
1572 Tripathi et al Gastroenterology Vol. 155, No. 5
BASIC
AND
TRANSLATIONAL
LIVERdescribing that polymorphonuclear cells like neutrophils
rapidly react by migrating to inﬂammation sites,6 forming
NETs, and contributing to the inﬂammation-associated liver
damage by releasing reactive oxygen species, proteolytic
enzymes, and inﬂammatory mediators.47,48 Moreover, we
describe a novel inﬂammatory mechanism involved in the
pathophysiology of ACLF: activated neutrophils might per se
contribute to HSC activation through an intercellular inter-
action, therefore representing a novel therapeutic target for
this syndrome.
Finally, considering the severity of ACLF in humans, we
evaluated short-term mortality in this preclinical model of
ACLF. LPS administration negatively affected survival and
biochemical parameters in all cirrhotic groups, although the
effects were more evident in decompensated animals.
Altogether, these data suggest that the ACLF model
presented herein appears to be a proper model mimicking
the clinical ACLF syndrome observed in cirrhotic patients.49
As previously stated, no speciﬁc treatment is available
for ACLF patients. However, different studies have shownthat statins improve portal hypertension and survival in
cirrhosis without ACLF11,17,18,50–52 and ameliorate vascular
function during sepsis.20,26,53,54 In this study, we report for
the ﬁrst time to our knowledge that simvastatin prevents
the endotoxemia-induced aggravation of chronic liver dis-
ease, with improvements in hepatic hemodynamic, inﬂam-
mation, oxidative stress, and survival both in
decompensated and compensated cirrhotic animals,
although a greater protection was observed in decom-
pensated CCl4-cirrhotic rats.
Underlying mechanisms of simvastatin-derived protec-
tion may be multiple9: simvastatin confers vasoprotection in
both normal and cirrhotic rat livers13 and has a broad
spectrum of anti-inﬂammatory and immunomodulatory ef-
fects. In fact, rats pretreated with simvastatin exhibited
improved hepatic sinusoidal function, which prevented
portal hypertension aggravation due to LPS and conferred
both hepatic and systemic anti-inﬂammatory effects in
cirrhotic rats with LPS-induced ACLF, thus suggesting
possible extrahepatic protection in cirrhosis.18
Figure 5. Effects of ACLF
on the HSC phenotype in
rats with ACLD treated
with simvastatin or vehicle.
HSC activation marker a-
SMA was analyzed at the
messenger RNA and pro-
tein expression levels in (A)
CCl4 and (B) BDL decom-
pensated ACLD rats
treated with vehicle (veh,
n ¼ 9 in CCl4 and n ¼ 8 in
BDL), vehicle þ LPS
(veh þ LPS, n ¼ 12 in CCl4
and n ¼ 7 in BDL), or
simvastatin þ LPS
(Simva þ LPS; n ¼ 9 in
CCl4 and n ¼ 8 in BDL).
Values represent mean ±
standard error of the
mean. *P < .05. a-SMA,
a-smooth muscle actin;
GAPDH, glyceraldehyde-
3-phosphate
dehydrogenase.
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decreased hepatic oxidative stress and improved nitric ox-
ide production during ACLF. Such ameliorations were
associated with signiﬁcant improvement in HSC phenotype,
which may also be partly due to reduced number of inﬁl-
trated neutrophils and NETs. However, we did not observe a
reduction in collagen deposition in simvastatin-treated rats,
probably because short-term simvastatin treatment may
promote only HSC deactivation, whereas ﬁbrosis reduction
would require a much longer treatment period.
The described analysis is derived from survivors (those
cirrhotic animals that resisted LPS challenge), and therefore
it is plausible that the effects of ACLF on hepatic hemody-
namics, inﬂammation, and liver cell phenotype, but also the
protection conferred by simvastatin, in reality would be
much more pronounced. In agreement with this, we did not
observe evident aggravation in extrahepatic organs in
cirrhotic animals with ACLF, which may be seen as a limi-
tation of the model. Indeed, mild renal injury was suggestedby elevated levels of plasma neutrophil gelatinase–
associated lipocalin with no changes in creatinine levels.
However, and as stated earlier, this may derive from the fact
that we analyzed only those animals that survived to LPS
administration, or multiorgan failure demonstration may
require longer periods of LPS challenge.
In conclusion, development of ACLF due to LPS admin-
istration markedly exacerbated hepatic and systemic in-
ﬂammatory pathways, leading to a profound aggravation of
the already dysfunctional hepatic microvasculature and to
decreased survival of cirrhotic animals. Simvastatin pre-
vented these deregulations, mainly by avoiding the inﬂam-
matory burst, oxidative stress, and sinusoidal cell
dysfunction. Considering our results reported here and
previous studies,17,19,28 we propose simvastatin as a safe
and useful therapeutic strategy for cirrhotic patients un-
dergoing ACLF. A large-scale clinical trial will evaluate the
possible beneﬁcial effects of this compound in patients with
decompensated cirrhosis.55
Table 2. Initial and Final Number of Animals and Survival Rate in Rats With Decompensated and Compensated ACLD
Survival table
Decompensated ACLD
CCl4 BDL
Initial No.
of Animals
Final No.
of Animals % of Survival
Initial No.
of Animals
Final No.
of Animals % of Survival
Vehicle 9 9 100 8 8 100
Vehicle þ LPS 18 12 66.6a 12 7 58.3a
Simvastatin þ LPS 9 9 100b 9 8 88.9c
Compensated ACLD
CCl4 TAA
Initial No.
of Animals
Final No.
of Animals % of Survival
Initial No.
of Animals
Final No.
of Animals % of Survival
Vehicle 5 5 100 4 4 100
Vehicle þ LPS 8 6 75 6 3 50
Simvastatin þ LPS 7 6 85.7 6 5 83.3
aP < .05 vs vehicle.
bP < .05 vehicle þ LPS vs simvastatin þ LPS.
cP < .10 vs vehicle þ LPS.
Table 3.Effects of LPS and Simvastatin on Biochemical Parameters in Rats With Decompensated and Compensated ACLD
Parameters
Decompensated ACLD
CCl4 BDL
Vehicle Vehicle þ LPS Simvastatin þ LPS Vehicle Vehicle þ LPS Simvastatin þ LPS
Number of animals 9 12 9 8 7 8
AST (U/L) 193 ± 136 522 ± 399a 247 ± 161d 423 ± 156 763 ± 613 997 ± 571c
ALT (U/L) 84 ± 47 172 ± 125c 98 ± 32 68 ± 14 80 ± 52 122 ± 82
Total bilirubin (mg/dL) 0.27 ± 0.27 2.10 ± 0.76a 0.32 ± 0.27b 7.83 ± 2.07 6.94 ± 1.87 5.60 ± 1.66a
Albumin (g/L) 23 ± 5 23 ± 4 26 ± 2d 25 ± 4 20 ± 6 20 ± 7
Creatinine (mg/dL) 0.53 ± 0.19 0.65 ± 0.24 0.67 ± 0.18 0.80 ± 0.15 0.79 ± 0.24 0.70 ± 0.29
Sodium (mEq/L) 170 ± 18 176 ± 25 169 ± 21 187 ± 25 173 ± 26 160 ± 17c
Ammonia (mmol/L) 263 ± 153 392 ± 193 167 ± 127b 376 ± 135 514 ± 220 592 ± 213c
Parameters
Compensated ACLD
CCl4 TAA
Vehicle Vehicle þ LPS Simvastatin þ LPS Vehicle Vehicle þ LPS Simvastatin þ LPS
Number of animals 5 6 6 4 3 5
AST (U/L) 161 ± 139 135 ± 51 166 ± 66 149 ± 60 1060 ± 2200 156 ± 37
ALT (U/L) 78 ± 57 50 ± 18 72 ± 25 59 ± 7 381 ± 796 46 ± 15
Total bilirubin (mg/dL) 0.10 ± 0.00 0.86 ± 0.53a 0.13 ± 0.05b 0.12 ± 0.05 0.61 ± 0.27a 0.12 ± 0.04b
Albumin (g/L) 30 ± 2 28 ± 3 28 ± 4 32 ± 3 34 ± 3 32 ± 4
Creatinine (mg/dL) 0.65 ± 0.21 0.67 ± 0.12 0.59 ± 0.06 0.48 ± 0.09 0.85 ± 0.38 0.81 ± 0.29
Sodium (mEq/L) 172 ± 12 179 ± 5 178 ± 13 189 ± 5 176 ± 14 172 ± 24
Ammonia (mmol/L) 166 ± 127 166 ± 59 183 ± 140 255 ± 117 357 ± 127 297 ± 141
NOTE. Values represent mean ± standard deviation.
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
aP < .05 vs vehicle.
bP < .05 vehicle þ LPS vs simvastatin þ LPS.
cP < .10 vs vehicle.
dP < .10 vs vehicle þ LPS.
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